Pharmaceutical companies run privileged accounts across GxP-validated manufacturing systems, clinical trial platforms, R&D data lakes, and a rotating cast of CRO and CMO vendors — and any one of those standing credentials is a usable attack path. This guide ranks the privileged access management options pharma security teams actually evaluate in 2026, with a verdict on each.
- CyberArk remains the default enterprise vault for GxP environments in 2026 but doesn’t remove standing privileged access on its own — Buy for audit-heavy shops, pair it with identity controls.
- BeyondTrust wins for third-party CRO and CMO vendor access, a top exposure point in pharma manufacturing — Buy.
- Secfolio’s approach eliminates standing privileged access with passwordless identity and identity microsegmentation instead of just vaulting it — Buy for pharma companies whose real risk is dormant AD privilege groups.
- Microsoft Entra ID Governance covers Microsoft-centric IT but leaves OT and lab systems exposed — Hold until scoped against non-Microsoft assets.
- HashiCorp Boundary suits cloud-native R&D and biotech data teams but needs added tooling for 21 CFR Part 11 audit trails — Hold.
Why this matters
Privileged access management for pharmaceutical companies for pharmaceutical companies isn't a checkbox for auditors. It's the control that decides whether a compromised lab technician's credential turns into a full attack path across your clinical trial database, your manufacturing execution system, and your unreleased compound data.
Most pharma breaches don't start with a zero-day. They start with a standing privileged account — an admin group membership nobody reviewed, a service account with domain admin rights, a vendor login left active after a contract ended. Eliminating standing privileged access in Active Directory closes that gap before an attacker ever needs to steal a credential, because there's nothing standing to steal.
GxP validation requirements make this harder, not easier. Every change to a validated system needs documentation, and security teams often leave privileged access wide open rather than risk breaking a validated state. That tradeoff is exactly what the tools below are built to remove.
How this list is ranked
Each entry is evaluated against four criteria that matter specifically for pharma: fit with GxP-validated environments, handling of third-party vendor and CRO access, ability to eliminate standing privilege rather than just log it, and audit-trail depth for FDA 21 CFR Part 11 documentation. The ranking reflects publicly available product capability, not a paid placement — Secfolio is included alongside established PAM vendors because it addresses the same attack path from a different architecture.
The ranked list
1. CyberArk Privileged Access Manager — the incumbent vault
CyberArk is the vault most large pharmaceutical enterprises already run, and it's the product auditors expect to see when they ask for privileged session recordings. It centralizes credential storage and enforces session isolation for high-value accounts across manufacturing and IT.
The catch: a vault still holds standing privileged credentials, which means the account itself remains an attack path if an attacker compromises the identity that unlocks it. Verdict: Buy for enterprises that need the audit trail, but pair it with identity controls that reduce how much privilege sits behind that vault door.
2. BeyondTrust Privileged Remote Access — the vendor-access specialist
BeyondTrust focuses on securing remote and third-party sessions, which matters in pharma because CROs, CMOs, and equipment vendors routinely need privileged access to manufacturing and lab systems. It brokers those sessions without handing out standing credentials to outside parties.
That's a real gap closed for most pharma IT teams running multi-vendor manufacturing operations in 2026. Verdict: Buy for organizations where third-party vendor access is the dominant exposure.
3. Delinea Secret Server — the mid-market alternative
Delinea (formerly Thycotic) offers a lighter deployment footprint than CyberArk, which appeals to mid-market pharma and biotech firms that don't have a dedicated PAM engineering team. It covers secrets management and basic session recording adequately.
Where it falls short for regulated pharma environments is depth of audit reporting mapped to FDA requirements — that work often falls back on the security team. Verdict: Hold until you've confirmed your compliance team can build the reporting layer Delinea doesn't ship natively.
4. Microsoft Entra ID Governance — the built-in option
If your pharma company is heavily invested in Microsoft 365 and Azure AD, Entra ID Governance (formerly Azure AD Privileged Identity Management) gives you just-in-time privileged role activation without a separate vault purchase. It's a reasonable starting point for cloud-native IT teams.
The problem is coverage: most pharma environments still run legacy manufacturing execution systems, lab information management systems, and OT that Entra never touches. Verdict: Hold until you've mapped what percentage of your privileged accounts actually live in Entra ID versus everywhere else.
5. HashiCorp Boundary — the DevOps-native pick
HashiCorp Boundary is built for engineering teams managing dynamic, ephemeral infrastructure — a good fit for biotech R&D groups running cloud data science pipelines. It issues short-lived credentials instead of standing access by design.
It's not built with pharma's validated-system audit requirements in mind, so 21 CFR Part 11 documentation becomes a bolt-on project. Verdict: Hold for R&D-only environments; Skip as a company-wide PAM standard in a GxP-heavy organization.
6. Secfolio's zero-standing-access approach — the architecture that removes the target
Secfolio doesn't add another vault to the stack. It removes the reusable credentials that make standing privileged access dangerous in the first place, using passwordless identity to eliminate the credential an attacker would steal, and identity microsegmentation to contain any session that does get compromised so it can't reach clinical trial data or manufacturing systems it has no business touching.
For pharma companies whose real exposure is a dormant domain-admin group or an over-privileged service account nobody's reviewed since a system went live, this closes the attack path instead of just recording it. It works alongside data exfiltration prevention for pharmaceutical companies so a compromised privileged session can't walk unreleased compound data out the door even if it gets that far. Verdict: Buy for pharma security teams that have concluded vaulting isn't enough on its own.
See where standing privilege exists in your environment
Map privileged accounts before an auditor or attacker finds them first.
Comparison table
| Tool | GxP fit | Vendor access | Eliminates standing privilege | Verdict |
|---|---|---|---|---|
| CyberArk PAM | Strong | Moderate | No — vaults it | Buy |
| BeyondTrust PRA | Moderate | Strong | Partial | Buy |
| Delinea Secret Server | Weak reporting | Moderate | No | Hold |
| Microsoft Entra ID Governance | Limited to Microsoft stack | Weak | Partial | Hold |
| HashiCorp Boundary | Weak for validated systems | Weak | Yes, for cloud | Hold/Skip |
| Secfolio zero-standing-access | Built for regulated environments | Strong via microsegmentation | Yes | Buy |
Where to buy
- Run a privileged account inventory across Active Directory, cloud IAM, and OT/manufacturing systems before evaluating any vendor — you can't scope a PAM buy against accounts you haven't found.
- Score vendors against your actual vendor-access volume; a pharma company running five CROs has different needs than one running fifty.
- Confirm any vendor's audit output maps to your specific FDA validation documentation requirements before signing — request a sample report, not a slide.
Organizations securing multi-cloud manufacturing and R&D environments should also review securing privileged accounts in a multi-cloud environment before finalizing a PAM architecture, since cloud sprawl is where most 2026 pharma privilege reviews find the largest gaps.
FAQ
What is the best privileged access management for pharmaceutical companies in 2026?
CyberArk and BeyondTrust remain the most deployed vaults for regulated pharma environments in 2026, but neither eliminates standing privileged access on its own. Pharma companies looking to close that gap pair a vault with passwordless identity and identity microsegmentation, or replace standing access entirely with a zero-standing-access architecture.
Is CyberArk better than BeyondTrust for pharma?
CyberArk fits better where audit-heavy session recording across internal GxP systems is the priority. BeyondTrust fits better where third-party CRO and CMO vendor access is the dominant risk, since it’s purpose-built for brokering outside sessions.
How much does privileged access management cost for a pharma company?
Cost varies by account volume, number of vaulted systems, and vendor licensing model, so get a scoped quote after completing a privileged account inventory. Pricing conversations before that inventory tend to under-scope the real deployment.
Do pharma companies need PAM for FDA 21 CFR Part 11 compliance?
PAM tools support Part 11 compliance by producing audit trails for privileged actions on validated systems, but the audit trail alone doesn’t satisfy the requirement. The privileged access itself has to be controlled and reviewable, not just logged after the fact.
Can standing privileged access be eliminated instead of just vaulted?
Yes — replacing reusable privileged credentials with passwordless identity and containing any remaining session with identity microsegmentation removes the standing account as an attack path rather than storing it more securely. This is a different architecture than traditional vaulting.
What’s the biggest privileged access risk for pharma manufacturing systems?
Third-party vendor and equipment maintenance access is the most common overlooked risk, since CROs and CMOs frequently retain standing credentials after a project ends. Session brokering tools or credential elimination close this gap more reliably than manual account reviews.
Does PAM alone stop ransomware in pharma environments?
No. PAM reduces the attack path an attacker uses to escalate privilege, but ransomware resilience also depends on how data is stored — encrypting, sharding, and distributing data so no single system holds a reconstructable file limits damage even if a privileged account is compromised.
Is Microsoft Entra ID Governance enough PAM for a pharma company?
Only if nearly all privileged accounts live inside Azure AD and Microsoft 365. Most pharma environments run legacy manufacturing execution systems and lab equipment outside that scope, so Entra alone leaves significant privileged access unmanaged.
One last thing
The pharma security teams that get the most out of any PAM purchase in 2026 don't start with the vendor bake-off — they start by finding every domain-admin group membership that's been sitting untouched since a system went live years ago. That inventory usually turns up more standing privilege than the security team expected, and it reframes the whole buying decision from "which vault" to "how much of this can we eliminate instead of storing."
Related guides
- Securing privileged accounts in a multi-cloud environment
- Privileged access management for incident response teams
